Navigation Links
Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
Date:7/14/2008

COLUMBUS, Ohio, July 14 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its New Drug Application (NDA) for Morphine Sulfate Tablets and Oral Solution CII by the U.S. Food and Drug Administration. Roxane Laboratories' Morphine Sulfate CII is available in 15mg, 30mg tablet strengths and 10mg/5mL, 20mg/5mL oral solution strengths. Roxane Laboratories' Morphine Sulfate tablets and oral solutions CII are currently available for immediate shipment to wholesalers and pharmacies nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )

With this New Drug Application approval, Roxane Laboratories has the only FDA approved Morphine Sulfate Immediate Release Tablets and Oral Solution available for distribution in the United States.

Full prescribing information for Morphine Sulfate is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
2. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
3. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
4. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
11. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... , ... Curemark, LLC announced today that the Blüm Study, a Phase 3 ... with Autism, is now enrolling at three new sites. These new sites are in ... , “There are currently no approved drugs that address the core symptoms of autism,” ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... treatment to the thousands of individuals who have recently fallen victim to America’s opioid ... in Orange County, California, where they are free from the shame, stigma, and ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its ... Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission ... premise liability and other personal injury cases. These injuries have a major impact ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... The U.S. cannabis market is growing ... use in 2016. According to a new report published by ... estimated $7.2 billion in 2016 and is projected to grow ... recreational sales are projected to jump from $2.6 billion in ... The market may grow faster as the estimate was based ...
(Date:2/23/2017)... , Feb. 22, 2017 This report analyzes analyzes the ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. ... Market data and analytics are derived from primary and secondary ...
(Date:2/23/2017)... Ill. , Feb. 23, 2017 Takeda ... subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition ... PLC and Ctrl Group Limited, announced a collaboration to ... an Apple Watch wearable to monitor and assess cognitive ... Depression (MDD) is the leading cause of disability ...
Breaking Medicine Technology: